Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
复制标题
DOI：
10.1016/j.ijantimicag.2020.105924
复制
发表时间：
2020-03-01
影响因子：
10.8
通讯作者：
Hsueh, Po-Ren
中科院分区：
文献类型：
--
作者：
Lai, Chih-Cheng;Shih, Tzu-Ping;Hsueh, Po-Ren
2019年底，中国的严重急性呼吸综合征冠状病毒2（SARS-COV-2；先前以临时命名为2019年新颖的冠状病毒或2019-NCOV）疾病（Covid-19）疾病引起了大规模的全球疫情公共卫生问题。截至2020年2月11日，世界卫生组织（WHO）的数据表明，已在28个国家/地区确定了超过43 000例确认的案件，> 99％的案件在中国被发现。 2020年1月30日，世卫组织宣布Covid-19为第六次公共卫生紧急国际关注。 SARS-COV-2与两种蝙蝠衍生的严重急性呼吸综合症类冠状病毒，BAT-SL-COVZC45和BAT-SL-COVZXC21密切相关。它通过人类到人类的传播通过液滴或直接接触传播，据估计，感染的平均孵育周期为6.4天，基本繁殖数为2.24-3.58。在由SARS-COV-2（新型冠状病毒或武汉肺炎）引起的肺炎患者中，发烧是最常见的症状，其次是咳嗽。双侧肺与地面玻璃透明度的参与是胸部计算机断层扫描图像中最常见的发现。美国SARS-COV-2肺炎的一个病例对Remdesivir的反应很好，Remdesivir现在正在中国接受临床试验。当前，控制感染以防止SARS-COV-2的扩散是使用的主要干预措施。但是，公共卫生当局应继续密切监视情况，因为我们可以了解这种新颖的病毒及其相关疫情的越多，我们就会越有回应。 （c）2020 Elsevier B.V.和国际化学疗法学会。版权所有。
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China. On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest. The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.